For the Inventor, By the Inventor

Enter assignee name

International Institute of Cancer Immunology, Inc.

USPTO Granted Patents = 61

CIPO Patents = 11

EPO Patents = 34

Forward Citations = 407

Loading Chart...

Loading Chart...

27 inventors (with patents filed for the assignee):

Haruo Sugiyama (53 out of 68 patents)

Toshio Nishihara (7 out of 13 patents)

Masashi Gotoh (7 out of 8 patents)

4. Yoshihiro Oka (5 out of 6 patents)

5. Hitoshi Ban (4 out of 37 patents)

6. Masashi Goto (4 out of 33 patents)

7. Shinji Sogo (4 out of 4 patents)

8. Yosuke Takanashi (4 out of 10 patents)

9. Yusuke Oji (4 out of 7 patents)

10. Hideo Takasu (4 out of 4 patents)

11. Chiang Jia Li (3 out of 57 patents)

12. Fumihiro Fujiki (3 out of 4 patents)

13. Yoshihiro Goto (3 out of 6 patents)

14. Yukihiro Nishio (3 out of 9 patents)

15. Masayoshi Sato (2 out of 2 patents)

Core Competencies:

Cancer Immunotherapy

WT1 Antigen Peptide

Helper T Cell Activation

Cancer Vaccine Composition

Antigen-Specific T-Cell Receptor

Angiogenic Disease Treatment

HLA-DR-Binding Peptide

Tumor Antigen

Combination Therapy

Peptide Conjugate Vaccine

Clinical Effect Prediction

siRNA Specific to WT1

61 patents: Sort by Forward Citations

1. 12440546 - Composition for preventing or treating benign tumor (2025-10-14),

2. 12415833 - Method for activating helper T cell (2025-09-16),

3. 12383608 - WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides (2025-08-12),

4. 11759509 - WT1 antigen peptide conjugate vaccine (2023-09-19),

5. 11732018 - Cancer antigen helper peptide (2023-08-22),

6. 11707512 - Cancer vaccine composition (2023-07-25),

7. 11555814 - Method for activation of helper t cell and composition for use in the method (2023-01-17),

8. 11413322 - Immunotherapy for angiogenic disease (2022-08-16),

9. 11369656 - Immunotherapy for angiogenic disease (2022-06-28),

10. 11091531 - Antigen-specific helper T-cell receptor genes (2021-08-17),

11. 11027003 - HLA-DR-binding antigen peptide derived from WT1 (2021-06-08),

12. 10947503 - Method for modifying T cell population (2021-03-16),

13. 10815288 - Antigen-specific helper T-cell receptor genes (2020-10-27),

14. 10759840 - Cancer antigen helper peptide (2020-09-01),

15. 10669584 - Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them (2020-06-02),

The International Institute of Cancer Immunology, Inc. (IICI) is a leading research organization focused on advancing the understanding and treatment of cancer through immunology. Our mission is to harness the power of the immune system to combat cancer and improve patients' lives. We conduct groundbreaking research, collaborate with leading institutions, and develop innovative immunotherapies, including personalized cancer vaccines and immune checkpoint inhibitors. Our team of world-class scientists and clinicians work tirelessly to translate scientific discoveries into clinical applications, bringing new hope to cancer patients around the globe.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

61 Patents

#1 in Suita

#1,482 in Japan

#11,629 in the World

International Institute of Cancer Immunology, Inc.

Forward Citations = 407

27 inventors:

Haruo Sugiyama (53 out of 68 patents)

Toshio Nishihara (7 out of 13 patents)

Masashi Gotoh (7 out of 8 patents)

4. Yoshihiro Oka (5 out of 6 patents)

5. Hitoshi Ban (4 out of 37 patents)

Please report any incorrect information to support@idiyas.com

Loading…